24 results on '"Vens, C."'
Search Results
2. SP-1026 Against the motion
3. OC-0438: Clinical pharmacodynamics support biological effectivity of low dose olaparib as radiosensitizer
4. OC-0692: Phase 1 study of olaparib as radiosensitizer for locally advanced non-small cell lung cancer
5. Micro cone beam computed tomography for sensitive assessment of radiation-induced late lung toxicity in preclinical models
6. OC-0487: EMT signatures as a prognostic marker for metastasis in HPV-negative HNSCC
7. PO-1051: Comparative genomic analysis of oral versus laryngeal and pharyngeal cancer
8. PO-1049: HNSCC Cell Lines with DNA Repair Defects show an Invasive Phenotype in vitro
9. OC-0463: In vitro prediction of DNA repair defects reveals association with poor clinical outcome in HNSCC
10. SP-0208: Validation of imaging with histology: implications for dose prescriptions
11. OC-0258: Linear-quadratic modeling of acute rectum toxicity in a prostate hypo-fractionation trial
12. Results of phase I trials combining PARP inhibition and radiotherapy in multiple sites
13. OC-0339: More acute proctitis symptoms with hypofractionation (3.4 Gy) than 2 Gy fractions
14. 351 Sensitive pharmacodynamic assessment of PARP inhibitors for individualized treatment in clinic
15. PO-0713: Pathology of CTV of prostate cancer: implications for the dose to the tumor and the gland
16. OC-0617: The PARP inhibitor olaparib is effective as radiosensitizer at 10-fold lower doses than as single agent
17. OC-0051: Towards the clinic: application of μ-IGRT for assessment of radiationinduced pneumonitis and pulmonary fibrosis
18. PD-0427: A pharmacodynamic assay to assess the radiosensitizing potential of PARP inhibitors in clinical trials
19. PD-0426: Homologous recombination repair deficient tumor cells exhibit increased radiosensitization by PARP inhibition
20. OC-0483: DNA repair defects in squamous cell carcinomas of the head and neck
21. SP-0390: Radiotherapy and targeted drugs: which and how many pathway(s) to target?
22. P0-42: Targeting NAD+ Biosynthesis Combined with Radiation to Enhance Cell Death
23. OC-0068 THE NAD+ DEPLETING AGENT APO866 ENHANCES CELL DEATH WHEN COMBINED WITH RADIATION
24. SP-0526 OPPORTUNITIES OF DOSE MODIFIERS: ILLUSTRATING THE CONCEPTS AND OUTLINING THE FUTURE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.